|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, Vol. 93 No. 7 (April 1), 1999:
pp. 2267-2273
By
From the Center for Molecular and Vascular Biology, Katholieke
Universiteit Leuven, Leuven, Belgium; the Haemostasis Research Group,
MRC Clinical Sciences Centre, ICSM, London, UK; and the American Red
Cross, Holland Laboratory, Rockville, MD.
Two unrelated patients with the same Arg2150His mutation in the
factor VIII (FVIII) C1 domain, a residual FVIII activity of 0.09 IU/mL,
and inhibitor titres of 300 and 6 Bethesda Units, respectively, were
studied. Further analysis of patient LE, with the highest inhibitor
titer, showed that (1) plasma or polyclonal IgG antibodies prepared
from LE plasma inhibited the activity of allogeneic (wild-type) but not
of self FVIII; (2) the presence of von Willebrand factor (vWF)
increased by over 10-fold the inhibitory activity on wild-type FVIII;
(3) the kinetics of FVIII inhibition followed a type II pattern, but in
contrast to previously described type II inhibitors, LE IgG was
potentiated by the presence of vWF instead of being in competition with
it; (4) polyclonal LE IgG recognized the FVIII light chain in
enzyme-linked immunosorbent assay and the recombinant A3-C1 domains in
an immunoprecipitation assay, indicating that at least part of LE
antibodies reacted with the FVIII domain encompassing the mutation
site; and (5) LE IgG inhibited FVIII activity by decreasing the rate of
FVIIIa release from vWF, but LE IgG recognized an epitope distinct from ESH8, a murine monoclonal antibody exhibiting the same property. We
conclude that the present inhibitors are unique in that they clearly
distinguish wild-type from self, mutated FVIII. The inhibition of
wild-type FVIII by LE antibody is enhanced by vWF and is associated with an antibody-dependent reduced rate of FVIIIa release from vWF.
THE INCIDENCE OF inhibitory antibodies in
patients with hemophilia A is still a matter of controversy, with
reported incidences varying from 5% to 52%, depending to some extent
on the underlying factor VIII (FVIII) gene defect. Thus, in severe hemophilia (FVIII activity < 0.01 IU/mL) a higher risk is associated with mutation types such as large deletions, nonsense mutations, and
gene inversion than with missense mutations.1
Moderate/mild hemophilia (FVIII activity Antibodies inhibiting allogeneic (wild-type) but not self FVIII are
exceptional. A single case report described a patient with moderate
hemophilia A associated with a mutation in the FVIII A2 domain and in
whom significant FVIII activity coexisted with a low titer of
inhibitor.3 Anti-FVIII antibodies were shown to be
directed, at least in part, toward the wild-type region corresponding
to the mutated site of the heavy chain.
Observations such as these are of outstanding interest because they are
likely to shed light on the mechanisms by which tolerance to FVIII is
established and maintained, and vice-versa, by which tolerance to self
is broken. In fact, the immune response to FVIII might represent a
unique opportunity to study such mechanisms as it can be elicited in
the context of alloimmunization and autoimmunization.4
We report here on two unrelated patients with mild hemophilia
associated with a Arg2150His mutation in the C1 domain of FVIII. These
patients maintained significant FVIII activity despite the development
of high-titer anti-FVIII antibody. One of these patients was studied in
more detail, and the data show that the findings were not due to the
kinetics of FVIII inactivation but rather to epitope specificity of the
inhibitor, so that wild-type but not the patient's own variant FVIII
was inhibited.
Reagents and Buffers
Patient Histories
Antibody Purification An IgG fraction of LE inhibitor plasma was obtained by affinity chromatography on protein G Sepharose. The amount of IgG antibodies recovered by affinity purification was measured by specific enzyme-linked immunosorbent assay (ELISA) as described previously.5FVIII Biotinylation rFVIII was diluted at 100 µg/mL in 10 mmol/L HEPES, 0.15 mol/L NaCl pH 8.5, and incubated with 1 µg/mL sulfo-NHS-LC biotin (Pierce) for 30 minutes at room temperature (RT). Excess of biotin was then removed by dialysis against HEPES 20 mmol/L, NaCl 0.15 mol/L, CaCl2 10 mmol/L, pH 7.2. This labeling procedure did not significantly alter FVIII activity as evaluated in a FVIII chromogenic assay.FVIII Antigen Assay FVIII antigen levels were determined by a sandwich-type ELISA. Microtitration plates (EIA/RIA plates, Costar, Cambridge, MA) were coated by overnight incubation at 4°C with 200 µL of PBS containing 5 µg/mL of MoAbF15B12 (prepared in our laboratory) with specificity for the FVIII A2 domain. The plates were then washed with PBS-Tween and blocked by incubation with PBS containing 1% BSA and 0.02% Tween-20 for 1 hour at RT. Two hundred microliters of 10-fold diluted hemophilic patient plasma or normal plasma pool as a control were then added for a further incubation of 90 minutes at RT. The plates were then washed as above before addition of peroxidase-conjugated MoAbF26B7 (prepared in our laboratory) directed toward the FVIII acidic region of the light chain (amino-acid residues 1649-1689) and diluted in PBS at 2 µg/mL. After an incubation of 1 hour at RT and a wash, the binding of the peroxidase-conjugated MoAb was detected by addition of OPD dissolved in citrate phosphate buffer, pH 5, which contained 3% H2O2. Absorbance was read at 492 nm. Normal plasma pool dilutions were used to construct a reference curve, against which the values obtained with samples under investigation were determined. Results are expressed as percentages of normal FVIII antigen values.vWF Antigen Assay vWF antigen assay was performed using ELISA6 based on two murine monoclonal antibodies.FVIII Genetic Analysis Sequence determination of patient LE FVIII gene was performed by the MRC Hemostasis Research Group. Exons 23 to 26 and the adjacent intronic sequences were amplified by polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis was performed as described by Michaelides et al.7 The PCR product, which showed aberrant mobility, was directly sequenced using the ABI PRISM Dye Terminator Sequencing Ready Reaction kit and Amplitaq DNA Polymerase FS according to the manufacturer's instructions (Perkin-Elmer Applied Biosystems, Warrington, UK) and analyzed on an ABI Applied Biosystems 373A DNA automated sequencer (Perkin-Elmer). Mutation analysis for patient MV was performed by fluorescent chemical cleavage of mismatches (FluoCCM) as described.8 Briefly, total RNA was extracted from peripheral blood lymphocytes. RNA extraction was performed using a modified guanidinium thiocyanate method. One picomole of fluorescent isothiocyanate (FITC)-labeled reverse-transcription polymerase chain reaction (RT-PCR) products from a patient and a control individual were mixed, denatured, and allowed to reanneal overnight at 65°C to form heteroduplexes. Mismatches were labeled with hydroxylamine and osmium tetroxide, respectively, as follows: treatment with hydroxylamine (5 mol/L, pH 6) for 60 minutes at 37°C and with osmium tetroxide (0.4%) for 15 minutes at RT. Reactions were stopped by adding 200 µL of precipitation buffer (0.1 mmol/L Na2EDTA pH 8.0, 300 mmol/L Na-Acetate). After ethanol precipitation, pellets were resuspended in 1 mol/L piperidine for 30 minutes at 90°C for cleavage of modified mismatches (C and T). The products were sized on a 4% denaturing polyacrylamide gel on the automated A.L.F. DNA sequencer (Pharmacia Biotech) on the same day. Fluorescent signals were analyzed with the Fragment Manager software (Pharmacia Biotech, Roosendaal, The Netherlands). The thermo sequenase fluorescent-labeled primer cycle sequencing kit with 7-deaza-dGTP (Amersham, Buckinghamshire, CA) was used for cycle sequencing to identify the mutation.FVIII Functional Assays FVIII activity was measured in a one-stage assay9 adapted to an automated coagulometer ACL-810 (Instrumentation Laboratory [IL], Milan, Italy) using severe hemophilia A plasma and a micronized silica aPTT reagent (IL), or in a chromogenic assay according to the manufacturer's instructions (Coatest, Kabi Vitrum, Brussels, Belgium). FVIII inhibitor levels were measured according to the Bethesda method,10 using blood collected in buffered trisodium citrate and predilution in FVIII-deficient plasma. Inhibitor plasmas were also tested in a modified Bethesda assay, in which normal pooled plasma was replaced by plasma of the hemophilic brother of LE (obtained after DDAVP administration), plasma-derived, or recombinant FVIII concentrates.Immunoprecipitation Assays These were performed as described.11,12 Briefly, duplicate samples of 50 µL inhibitor plasma diluted in Tris-buffered saline (TBS) containing 1% BSA were incubated with 10 µL 125I-labeled A1, A2, or C2 domains, or with full-length FVIII light chain (0.75 nmol/L, final concentration each) for 15 to 24 hours at 4°C with agitation, followed by 3 hours at the same temperature after addition of 100 µL TBS-BSA and 50 µL of a suspension of protein G-Sepharose beads. Beads were washed three times with TBS-Tween and radioactivity associated with them was determined in a gamma counter (LKB, Fredsforsstigen, Sweden). Background radioactivity without antibody was 1% to 2% of total radioactivity added, and maximal binding by antibody was 60% to 70%. Results are expressed as immunoprecipitation units per milliliter, as follows : 1 (Bound/Total Radioactivity Background) × Plasma Dilution × 16.7.
Release of Thrombin-Cleaved FVIII From vWF Polystyrene microtitration plates (Maxisorb, Nunc, Roskilde, Denmark) were coated by a 2-hour incubation at RT with 50 µL of an anti-human vWF MoAb (MoAb4H1D7, produced in our laboratory) diluted at 10 µg/mL in GBS. The plates were then washed 3 times with PBS-Tween and saturated for 30 minutes with 80 µL Tris-casein. Thirty microliters of a mixture of 10 µg/mL vWF and 1 µg/mL biotinylated rFVIII in Tris-casein was added to 30 µL of a human IgG sample adjusted to 2,000, 400, 80, or 16 µg/mL in the same buffer. Fifty microliters of this new mixture was added to the anti-vWF-coated plates for 2 hours at RT. The plates were washed as above before addition of 50 µL of thrombin diluted at 10 IU/mL in 9 g/L NaCl, 10 mmol/L CaCl2 for an incubation of 2 minutes at 37°C. Thrombin was then inhibited at once by addition of 50 µL of 10 µg/mL hirudin diluted in 9 g/L NaCl, 10 mmol/L CaCl2. The plates were immediately washed as above before incubation with 50 µL avidin peroxidase diluted at 2 µg/mL in TBS-BSA 2.5%. Fifteen minutes later, after washing, OPD was added and absorbance read at 492 nm.Inhibition Assay Inhibition of the anti-FVIII antibody binding to insolubilized rFVIII by isolated rFVIII heavy and light chains was performed as described previously.14 Briefly, 50 µL of purified LE IgG at 18 mg/mL and 50 µL of rFVIII light or heavy chain at 10 µg/mL were mixed and incubated for 2 hours at 37°C. Fifty microliters was then taken and added to rFVIII-coated plates for a further 2-hour incubation at RT. After washing, residual bound human IgG was detected by addition of a peroxidase-labeled goat IgG specific to human IgG. Control experiments were prformed with mouse MoAbs specific to the FVIII light or heavy chain.Competition Assay To determine whether the epitopes recognized by LE IgG were located at, or close to, the region to which MoAbESH8 binds, a competition assay was performed. To this end, polystyrene microtitration plates (Maxisorb, Nunc) were coated for 2 hours at RT with 50 µL of MoAbESH8 diluted to 5 µg/mL in GBS. The plates were washed 3 times with TBS-Tween and then saturated for 30 minutes at RT with 80 µL Tris-casein. Thirty microliters of biotin-labeled rFVIII diluted at 1 µg/mL in Tris-casein (with or without vWF at 10 µg/mL) was mixed with 30 µL of a sample containing LE anti-FVIII IgG adjusted to 2 mg in the same buffer. In control experiments, rFVIII was mixed with MoAbESH8 at 40 µg/mL or with buffer. Fifty microliters of the mixture were added to the ESH8-coated plates for a 2-hour incubation at RT. The plates were washed as described above before addition of 50 µL avidin-peroxidase diluted at 1 µg/mL in TBS-BSA. After 30-minute incubation at RT and washing, OPD was added and absorbance was read at 492 nm. Control experiments included substitution of patient anti-FVIII antibodies by a preparation of 2 mg of multidonor pooled gammaglobulins.
Patient Description and Follow-Up Patient LE. At preoperative workup, LE showed a FVIII activity of 0.23 IU/mL. vWF antigen was 2.40 IU/mL and anti-FVIII antibody 305 Bethesda Units (BU)/mL. The relatively high FVIII and vWF levels were probably related to infection. rFVIII was infused at a dose of 67 U/kg body weight, which did not increase FVIII activity. However, after administration of desmopressin acetate (0.3 µg/kg), FVIII activity increased to 0.45 IU/mL. The hemophilic brother of the patient, LM, had a basal FVIII level of 0.09 IU/mL and a FVIII antigen level of 11%, with no measurable inhibitor. After infusion of desmopressin an increase of FVIII activity to 0.97 IU/mL was measured. During and after surgical removal of the infected hip prosthesis (Girdle stone procedure), patient LE was treated by continuous infusion15 of recombinant factor VIIa (Novo-Seven, generously supplied by Novo-Nordisk Belgium for compassionate use) to maintain a level of factor VII:c at about 10 U/mL for a period of 12 days. A collection of 800 mL of pus was drained without bleeding complications. The postoperative course was, however, complicated by septicemia and the formation of a large abscess in the right thigh with fistulization to the skin. Blood loss occurred through the fistula on several occasions that required blood replacement and DDAVP administration. Except for this, no bleeding or abnormal activation of coagulation (tested by evaluation of D-Dimer, platelet count and fibrinogen levels) was observed during the entire postoperative period. The fistula eventually closed after more than 1 year, and the patient is presently well. One year after surgery, the FVIII level, vWF antigen, and inhibitor level were 0.09 IU/mL, 1.0 IU/mL, and 25 BU/mL, respectively. Patient MV. In patient MV an inhibitor of 4 BU/mL was detected at a routine outpatient visit. FVIII activity was, however, unchanged from his basal level (0.04 IU/mL), with a FVIII antigen level of 5%. Cumulative exposure days before inhibitor detection were 102 with FVIII SD (Belgian Red Cross) and 82 with Recombinate (Baxter). FVIII recovery was decreased to 0.26 IU/IU FVIII administered per kg body weight. After infusion of desmopressin (0.3 µg/kg body weight) FVIII activity rose from 0.04 IU/mL to 0.57 IU/mL. The inhibitor level increased to 6 BU/mL 6 weeks after first detection and was still at 4 BU/mL with a FVIII activity of 0.04 IU/mL 5 months later, although the patient had not been further exposed to FVIII concentrates. LE Plasma Inhibits Wild-Type but not Arg2150His Mutated FVIII Figure 1 shows that comparable levels of FVIII inhibition were obtained when LE plasma was mixed with either normal pooled plasma, plasma-derived FVIII, or rFVIII. The latter two were prediluted in severe hemophilia A plasma for testing by a modified Bethesda assay. An inhibition of 90% of FVIII activity was achieved even when undiluted patient plasma was used (data not shown). By contrast, no inhibition of `autologous' FVIII in plasma obtained from the mild hemophilic brother LM 30 minutes after DDAVP infusion (FVIII:c 0.97 IU/mL) was observed (Fig 1). However, the FVIII of LM was readily inactivated by mixing with plasma of a severe hemophilia A patient (BO) with high titer inhibitor (data not shown).16 Patient LE plasma did not inhibit the FVIII activity in patient MV plasma (result not shown).
LE Inhibitor Requires the Presence of vWF for Full Inhibitory Activity To get further insight into the mechanisms by which LE plasma inhibited wild-type but not self FVIII, we purified IgG as described in Materials and Methods. IgG inhibited both plasma-derived and rFVIII, prediluted in severe hemophilia plasma, but not self FVIII in a chromogenic assay, in a manner similar to what was observed using plasma. However, when purified IgG was mixed with rFVIII prediluted in buffer instead of FVIII-deficient plasma, only a limited inhibition was obtained. This suggested that a plasma factor, possibly vWF, was required for full expression of inhibitory activity. Therefore, we repeated the assay in the presence of purified vWF. As shown in Fig 2, addition of vWF (vWF:FVIII, 50/1, wt/wt ratio) increased by ±10-fold the inhibitory capacity of LE IgG on rFVIII activity, bringing it to the same level as that obtained using plasma-derived FVIII.
LE Antibodies Behave as Type II Inhibitors Because LE inhibitor did not completely inactivate wild-type FVIII, we evaluated the kinetics of FVIII inactivation compared to that obtained with the plasma of a severe hemophilia A patient (BO) with a known type I inhibitor. To this end, both preparations were diluted to an inhibitory level of 10 BU/mL. After mixing with normal plasma and incubation at 37°C for various time intervals, residual FVIII activity was measured in the mixture. Figure 3 shows that inactivation of plasma FVIII activity by LE IgG was slow and incomplete, ie, properties characteristic of type II inhibitors, whereas a rapid and complete inactivation was obtained with BO IgG.
LE Inhibitor Reacts With the A3-C1 Domains of FVIII Light Chain The enhancing effect of vWF on the inhibitory properties of LE IgG suggested that the corresponding epitope(s) could be located on the FVIII light chain.17 In an attempt to identify such an epitope on wild-type FVIII, we performed a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with native or thrombin-digested FVIII, followed by immunoblotting with LE IgG. No binding of IgG was detected (data not shown), suggesting that the epitope(s) was conformational rather than linear and/or that an additional factor was required for efficient antibody binding. The binding of patient LE IgG to insolubilized rFVIII was inhibited by more than 90% when LE IgG were preincubated with the isolated FVIII light chain; no inhibition was found after preincubation with isolated heavy chain (results not shown). Next, an immunoprecipitation assay was performed by mixing LE plasma either with the entire light chain, with isolated A1, A2, or C2 domains. Significant precipitation was obtained when full-length light chain was used but not with single domains (Table 1). However, assays performed with the combined 35S-rA3-C1 domains were positive with both LE and MV plasmas (Fig 4), indicating that at least some of the anti-FVIII antibodies of LE and MV are directed toward A3-C1.
LE IgG Decreases the Dissociation Rate of FVIIIa From vWF We next investigated whether the mechanism by which LE IgG inactivated FVIII was related to an antibody-dependent reduction in the dissociation from vWF. This was evaluated in an ELISA system. Thus, biotinylated FVIII-vWF complexes were mixed with different concentrations of either LE IgG, normal IgG, or MoAbESH8. The mixtures were then insolubilized on microtitration plates coated with an anti-vWF MoAb. FVIII was then activated by thrombin and the effect of antibodies on FVIIIa dissociation was measured by addition of avidin-peroxidase (Fig 5). The presence of normal IgG antibodies had no influence on the amount of residual FVIII bound to the plates. However, in the presence of LE IgG, a dose-related increase in residual FVIII was observed. MoAbESH8 showed the same effect, but polyclonal IgG of patient BO, known to displace FVIII from vWF,16 decreased in a dose-dependent manner the amount of residual bound FVIII. These findings suggested that at least part of the mechanism of action of LE IgG could be similar to that of MoAbESH8. In addition, we showed that LE IgG did not reduce the rate of FVIII activation by thrombin (data not shown). Therefore, we checked whether LE IgG recognized the same epitope as MoAbESH8, which had been mapped to residues 2248-2285 in the C2 domain.18 To this end, microtitration plates were coated with MoAbESH8 and then incubated with biotin-labeled rFVIII with or without vWF, and in the presence or not of antibodies. LE IgG did not inhibit rFVIII binding to ESH8, independently of the presence of vWF, while a significant inhibition was obtained with ESH8 (Fig 6). This indicated that LE IgG and MoAbESH8 did not recognize the same FVIII epitope.
We describe here two unrelated patients with mild hemophilia A and a single missense mutation at amino acid position 2150 (Arg2150His) in the C1 domain of the FVIII light chain. They both presented with anti-FVIII antibodies coexisting with significant FVIII activity. LE inhibitor plasma was examined in more detail and was shown to neutralize wild-type but not self FVIII and to behave as a type II inhibitor, characterized by incomplete FVIII inactivation following more complex kinetics of inactivation than that of type I inhibitors. Moreover, the inhibitory activity was shown to be dependent on the presence of vWF, and immunoprecipitation was positive with the A3-C1 domains of the FVIII light chain.
Submitted June 1, 1998; accepted November 23, 1998.
Supported by research grant G.0292.98 of the Flemish Research Foundation. J.V. is the holder of the "Dr J. Choay Chair in Haemostasis Research."
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
Address reprint requests to Kathelijne Peerlinck, MD, Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Campus Gasthuisberg, O&N, Herestraat 49, B-3000 Leuven, Belgium; e-mail: kathelijne.peerlinck{at}med.kuleuven.ac.be.
1. Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J: Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 74:1402, 1995[Medline] [Order article via Infotrieve] 2. Hay CRM, Ludlam CA, Colvin BT, Hill FGH, Preston FE, Wasseem N, Bagnall R, Peake IR, on behalf of the UK Haemophilia Centre Directors Organisation, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E: Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost 79:762, 1998[Medline] [Order article via Infotrieve]
3.
Fijnvandraat K, Turenhout EAM, van den Brink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J:
The missense mutation Arg593 4. Jacquemin MG, Saint-Remy JMR: Factor VIII immunogenicity. Haemophilia 4:552, 1998[Medline] [Order article via Infotrieve]
5.
Gilles JGG, Arnout J, Vermylen J, Saint-Remy JMR:
Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.
Blood
82:2452, 1993 6. Tornai I, Declerck PJ, Smets L, Arnout J, Deckmyn H, Caekebeke-Peerlinck KMJ, Vermylen J: Measurement of von Willebrand factor antigen in plasma and platelets with an enzyme-linked immunosorbent assay based on two murine monoclonal antibodies. Haemostasis 21:125, 1991[Medline] [Order article via Infotrieve] 7. Michaelides K, Schwaab R, Lalloz MRA, Schmidt W, Tuddenham EGD: Mutational analysis: New mutations, in McPherson MJ, Hames BD, Taylor GR (eds): PCR2. A Practical Approach. Oxford, UK, Oxford, 1995, p 255. 8. Freson K, Peerlinck K, Aguirre T, Arnout J, Vermylen J, Cassiman J-J, Matthijs G: Fluorescent chemical cleavage of mismatches for the efficient screening of the factor VIII gene. Human Mut 11:470, 1998[Medline] [Order article via Infotrieve] 9. Langdell RD, Wagner RH, Brinkhous KM: Effect of antihemophilic factor on one-stage clotting tests: A presumptive test for haemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 41:637, 1953[Medline] [Order article via Infotrieve] 10. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869, 1975[Medline] [Order article via Infotrieve]
11.
Thompson AR, Murphy MEP, Liu ML, Saenko EL, Healey JF, Lollar P, Scandella D:
Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.
Blood
90:1902, 1997 12. Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D: Dominant C2 domain specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 79:62, 1998[Medline] [Order article via Infotrieve] 13. Lenting PJ, van de Loo JHP, Donath M-JSH, van Mourik JA, Mertens K: Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 271:7150, 1996 14. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J: Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 77:80, 1997[Medline] [Order article via Infotrieve] 15. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, Heim M, Martinowitz U: Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 75:432, 1996[Medline] [Order article via Infotrieve]
16.
Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JGG, Vermylen J, Saint-Remy JMR:
Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.
Blood
92:496, 1998
17.
Saenko EL, Shima M, Gilbert GE, Scandella D:
Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
J Biol Chem
271:27424, 1996
18.
Saenko EL, Shima M, Rajalakshmi KJ, Scandella D:
A role for the C2 domain of factor VIII in binding to von Willebrand factor.
J Biol Chem
269:11601, 1994 19. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borrett R: The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 23:125, 1972[Medline] [Order article via Infotrieve]
20.
Gawryl MS, Hoyer LW:
Inactivation of factor VIII coagulant activity by two different types of human antibodies.
Blood
60:1103, 1982 21. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM: Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 74:619, 1995[Medline] [Order article via Infotrieve]
22.
Kemball Cook G, Tuddenham EGD:
The factor VIII mutation database on the World Wide Web: The haemophilia A mutation, search, test and resource site
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T.-C. Hsu, K. P. Pratt, and A. R. Thompson The factor VIII C1 domain contributes to platelet binding Blood, January 1, 2008; 111(1): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jacquemin, V. Vantomme, C. Buhot, R. Lavend'homme, W. Burny, N. Demotte, P. Chaux, K. Peerlinck, J. Vermylen, B. Maillere, et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A Blood, February 15, 2003; 101(4): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stoilova-McPhie, B. O. Villoutreix, K. Mertens, G. Kemball-Cook, and A. Holzenburg 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography Blood, February 15, 2002; 99(4): 1215 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Spiegel Jr, M. Jacquemin, J.-M. R. Saint-Remy, B. L. Stoddard, and K. P. Pratt Structure of a factor VIII C2 domain-immunoglobulin G4{kappa} Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII Blood, July 1, 2001; 98(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jacquemin, R. Lavend'homme, A. Benhida, B. Vanzieleghem, R. d'Oiron, J.-M. Lavergne, H. H. Brackmann, R. Schwaab, T. VandenDriessche, M. K. L. Chuah, et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor Blood, August 1, 2000; 96(3): 958 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Liu, B. W. Shen, S. Nakaya, K. P. Pratt, K. Fujikawa, E. W. Davie, B. L. Stoddard, and A. R. Thompson Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure Blood, August 1, 2000; 96(3): 979 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jacquemin, A. Benhida, K. Peerlinck, B. Desqueper, L. Vander Elst, R. Lavend'homme, R. d'Oiron, R. Schwaab, M. Bakkus, K. Thielemans, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor Blood, January 1, 2000; 95(1): 156 - 163. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1999 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
TOP
ABSTRACT
INTRODUCTION
0.02 IU/mL), which is most
often caused by a missense mutation, is also traditionally considered
to carry a low risk of inhibitor development. However, more recent data
describe an incidence of inhibitor up to the level found in severe
hemophilia with a similar type of gene defect.
), plasma of patient's brother
(LM; 
), a plasma-derived FVIII concentrate (
), or rFVIII diluted
in the plasma of a severe hemophilia A patient (
). Residual FVIII
activity is expressed as percent of control.
), or rFVIII complexed with vWF at a 1:50 wt:wt ratio (
), or IgG from a hemophilia patient (BO) which
displaces FVIII from vWF (
Cys is related to antibody formation in a patient with mild hemophilia A.
Blood
89:4371, 1997
HAMSTers update (version 3.0).
Nucleic Acids Res
25:128, 1997